Evidence map›Paper›PMID 42555629›Full record

ArticlePloS one2026

Uncertainty-aware personalized estimation of Parkinson's disease severity from longitudinal speech.

Khondakar Ashik Shahriar

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Khondakar Ashik ShahriarDepartment of Electrical and Electronic Engineering, Bangladesh University of Engineering and Technology, Dhaka, Bangladesh.ORCID https://orcid.org/0009-0008-2571-7485

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is a progressive neurological disorder characterized by motor impairments whose severity is commonly assessed using the Unified Parkinson's Disease Rating Scale (UPDRS). Although clinically established, UPDRS assessment is inherently subjective, requiring in-person evaluation by trained specialists, limiting its suitability for frequent monitoring. Speech production is affected early in PD and provides a non-invasive modality for remote symptom assessment. In this study, an uncertainty-aware personalized framework is proposed for estimating PD severity from speech signals. The approach integrates longitudinal temporal modeling of longitudinal speech recordings with patient-specific representations and a probabilistic latent disease state. Continuous motor UPDRS scores are jointly estimated with data-driven ordinal disease severity stages, enabling both fine-grained regression and auxiliary ordinal prediction. Predictive uncertainty is explicitly quantified to characterize predictive variability within the proposed framework. The method is evaluated on a longitudinal speech dataset using a strict patient-wise split, ensuring that all test subjects are unseen during training. On the held-out test set, the proposed model achieves promising predictive accuracy (mean absolute error 0.56 UPDRS points, root mean squared error 0.74, and coefficient of determination R2 = 0.99) for motor UPDRS estimation. Ordinal severity classification attained an accuracy of 0.92 across three stages. Comparative experiments against classical machine learning methods and global temporal baselines demonstrate consistent performance improvements. These results demonstrate the potential of personalized, uncertainty-aware speech modeling for longitudinal PD severity estimation.

Indexed as

Parkinson DiseaseSpeechFemaleHumansLongitudinal StudiesMaleSeverity of Illness IndexUncertainty

Identifiers

PMID42555629
PMCPMC13440870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.